Dr. Kaufman Discusses Durable Responses to Avelumab in Merkel Cell Carcinoma

0 Views
administrator
administrator
07/17/23

Howard L. Kaufman, MD, a surgical oncologist at Rutgers Cancer Institute of New Jersey, discusses a study which showed further durable responses to avelumab (Bavencio) in patients with merkel cell carcinoma who progressed after chemotherapy.

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next